Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAYSHA GENE THERAPIES, INC.

(TSHA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
20.88(c) 20.95(c) 19.9(c) 18.5(c) 18.51(c) Last
59 365 72 409 625 447 160 273 45 647 Volume
+4.66% +0.34% -5.01% -7.04% +0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -156 M - -
Net cash position 2021 137 M - -
P/E ratio 2021 -4,53x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -183 M - -
Net cash position 2022 141 M - -
P/E ratio 2022 -4,18x
Yield 2022 -
Capitalization 711 M 711 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 38
Free-Float 58,1%
More Financials
Company
Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its product candidates include: TSHA-101, which is being developed for the treatment of GM2 gangliosidosis; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis... 
Sector
Biotechnology & Medical Research
Calendar
09/22 | 10:00am
More about the company
Ratings of Taysha Gene Therapies, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about TAYSHA GENE THERAPIES, INC.
09/15TAYSHA GENE THERAPIES ANNOUNCES PUBL : Methods & Clinical Development
BU
09/15TAYSHA GENE THERAPIES ANNOUNCES PUBL : Methods & Clinical Development
CI
09/08TAYSHA GENE THERAPIES : to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment o..
BU
09/01TAYSHA GENE THERAPIES : to Participate in Upcoming September Investor Healthcare Conferenc..
BU
08/25SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Wednesday
MT
08/25Taysha Gene Therapies Gets Europe Orphan Drug Designation for Epilepsy Treatment
DJ
08/25TAYSHA GENE THERAPIES : Says Epilepsy Treatment Gets Orphan Drug Designation From European..
MT
08/25TAYSHA GENE THERAPIES : Receives Orphan Drug Designation for TSHA-105 for the Treatment of..
BU
08/18TAYSHA GENE THERAPIES : Morgan Stanley Adjusts Taysha Gene Therapies' Price Target to $39 ..
MT
08/17TAYSHA GENE THERAPIES : Chardan Adjusts Price Target on Taysha Gene Therapies to $60 From ..
MT
08/17TAYSHA GENE THERAPIES : to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment o..
BU
08/16TAYSHA GENE THERAPIES : Wedbush Lifts Price Target for Taysha Gene Therapiesto $34 From $3..
MT
08/16TAYSHA GENE THERAPIES : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/16TAYSHA GENE THERAPIES' : Q2 Loss Narrows, Operating Expenses Rise; Secures Up to $100 Mill..
MT
08/16TAYSHA GENE THERAPIES : Reports Second Quarter 2021 Financial Results and Provides Corpora..
PU
More news
News in other languages on TAYSHA GENE THERAPIES, INC.

- No features available -

More news
Analyst Recommendations on TAYSHA GENE THERAPIES, INC.
More recommendations
Chart TAYSHA GENE THERAPIES, INC.
Duration : Period :
Taysha Gene Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAYSHA GENE THERAPIES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 18,51 $
Average target price 44,83 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
R. A. Session President, Chief Executive Officer & Director
Kamran Alam Chief Financial Officer
Sean P. Nolan Chairman
Suyash Prasad Chief Medical Officer, Head-Research & Development
Fred Porter Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
TAYSHA GENE THERAPIES, INC.-30.26%711
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021